Ambry

NEW YORK (GenomeWeb) — After more than three years offering clinical whole exome sequencing for pediatric and adult patients suspected of having rare genetic disorders, clinicians from Columbia University Medical Center have concluded that the approach is a feasible, useful, and timely option for

NEW YORK (GenomeWeb) – Memorial Sloan Kettering along with other academic research institutions and testing labs said they will launch a registry to collect the genomic and outcomes data of patients who have consented to prospective follow up after being tested with a multi-gene hereditary cancer

A US federal district court in Utah denied Myriad Genetics and other plaintiffs a preliminary junction that would have stopped Ambry Genetics from selling competing BRCA tests, even though the court determined this may harm Myriad's business.

NEW YORK (GenomeWeb News) – A US federal district court has denied Myriad Genetics and other patent holders' request for a preliminary injunction against competitor Ambry Genetics to stop it from performing and selling tests that gauge BRCA genetic mutations.

NEW YORK (GenomeWeb News) – Myriad Genetics and other parties are suing BioReference Laboratories' GeneDx alleging infringement of patents covering BRCA1 and BRCA2 genes.

Myriad Genetics last week launched its next-generation sequencing-based hereditary cancer panel to early-access users.

In the wake of the US Supreme Court's decision to strike down Myriad Genetics' patents on isolated BRCA1 and BRCA2 gene sequences, GeneDx this week become the latest laboratory to launch sequencing-based tests for inherited cancer that include those genes.

This article has been updated from a previous version that stated incorrectly that Gene by Gene has performed 1 million BRCA tests globally.

After being sued by Myriad Genetics for allegedly infringing its patents on BRCA1 and BRCA2 gene mutation testing, Ambry Genetics pushed back this week with its own countersuit accusing Myriad of antitrust violations.

NEW YORK (GenomeWeb News) – In response to Myriad Genetics' patent infringement lawsuit against Ambry Genetics, the Aliso Viejo, Calif.-based testing firm took its own legal action today by countersuing Myriad for antitrust violations.

Pages

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.